Pr Sylvain Ladoire
- Spécialité
- Oncologue médical, expert sein et urologie
- Hôpital
- Centre Georges-François Leclerc (Dijon)
- Derniers articles
-
- Study design of the phase III ADELA trial of elacestrant with or without everolimus in ESR1-mutated ER+/HER2- advanced breast cancer after progression on endocrine therapy plus a CDK4/6 inhibitor. (31 oct. 2026)
- PELICAN-IPC 2015-016/Oncodistinct-003: A randomized non-comparative phase II study of pembrolizumab in combination with neoadjuvant chemotherapy in HER2-negative inflammatory breast cancer. (31 oct. 2026)
- Prognostic Value of a Composite Score Incorporating Baseline [(18)F]FDG PET/CT and [(68)Ga]Ga-PSMA-11 PET/CT When Screening for [(177)Lu]Lu-PSMA Treatment Eligibility (PROFILE Study). (1 oct. 2026)
- An expression signature of 19 human endogenous retroviruses identifies immunogenic luminal breast cancers likely to respond to immunotherapy. (16 juin 2026)
- Chemo-prAIdict Breast: A deep learning solution for predicting residual disease on biopsies of breast cancer patients treated with neoadjuvant chemotherapy. (5 févr. 2026)